Key Learnings From NICE Single Technology Appraisals

Articles (4 in this collection)

1. Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective

   Authors (first, second and last of 12)

   • Mirre Scholte
   • Bram Ramaekers
   • Nigel Armstrong

   • Content type: Commentary
   • Open Access
   • Published: 08 May 2024

2. Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective

   Authors (first, second and last of 12)

   • Bradley M. Sugden
   • Sabine E. Grimm
   • Willem J. A. Witlox

   • Content type: Commentary
   • Open Access
   • Published: 07 May 2024

   • Pages: 615 - 618

3. Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

   Authors (first, second and last of 12)

   • Giovany Orozco-Leal
   • Eugenie Evelynne Johnson
   • Stephen Rice

   • Content type: Commentary
   • Published: 20 November 2023

   • Pages: 133 - 136

4. Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

   Authors (first, second and last of 9)

   • Diarmuid Coughlan
   • Oluwatomi Arisa
   • Stephen Rice

   • Content type: Commentary
   • Published: 05 October 2023

   • Pages: 5 - 9